Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.77 |
| ▸ | ESR2 | Q92731 | 17/20 | 0.77 |
| ▸ | MLNR | O43193 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7022140 | 1.00 | ESR1 (0.77) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL8344170 | 1.00 | ESR1 (0.77) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL8501958 | 1.00 | ESR1 (0.77) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL8344173 | 1.00 | ESR1 (0.77) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL7022128 | 1.00 | ESR1 (0.77) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL7023166 | 0.93 | ESR1 (0.66) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL8503140 | 0.93 | ESR1 (0.66) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL8341472 | 0.93 | ESR1 (0.66) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL7023161 | 0.93 | ESR1 (0.66) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL8341470 | 0.93 | ESR1 (0.66) | ESR1ESR2MLNRNR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0937057-B1 | NOVEL (-)-ENANTIOMERS OF CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK AS (DK) | 2003-01-15 | — | — | EP | claimed |
| EP-0937060-B1 | CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK AS (DK) | 2002-12-11 | — | — | EP | claimed |
| EP-0937062-B1 | NOVEL CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK AS (DK) | 2002-12-11 | — | — | EP | claimed |
| US-6316494-B1 | FOR THERAPY AND PROPHYLAXIS OF BONE LOSS, OSTEOPOROSIS, CARDIOVASCULAR DISEASES, COGNITIVE DISORDERS, MENOPAUSAL SYMPTOMS, INCONTINENCE, OBESITY, DYSMENORRHEA, DYSFUNCTIONAL UTERINE BLEEDING, ACNE, HIRSUTISM, POST-PARTUM LACTATION | NOVO NORDISK A/S (DK) | 2001-11-13 | — | — | US | claimed |
| US-20010021710-A1 | NOVEL CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 2001-09-13 | — | — | US | claimed |
| US-5994390-A | OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; UROGENITAL DISORDERS | NOVO NORDISK (DK) | 1999-11-30 | — | — | US | claimed |
| EP-0937059-A1 | NOVEL $i(TRANS)-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 1999-08-25 | — | — | EP | claimed |
| EP-0937057-A1 | NOVEL (-)-ENANTIOMERS OF CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 1999-08-25 | — | — | EP | claimed |
| WO-1998018771-A1 | NOVEL (-)-ENANTIOMERS OF CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 1998-05-07 | — | — | WO | claimed |
| WO-1998018774-A1 | NOVEL TRANS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 1998-05-07 | — | — | WO | claimed |
| EP-0937057-B1 | NOVEL (-)-ENANTIOMERS OF CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK AS (DK) | 2003-01-15 | — | — | EP | disclosed |
| EP-0937060-B1 | CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK AS (DK) | 2002-12-11 | — | — | EP | disclosed |
| EP-0937062-B1 | NOVEL CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK AS (DK) | 2002-12-11 | — | — | EP | disclosed |
| US-6316494-B1 | FOR THERAPY AND PROPHYLAXIS OF BONE LOSS, OSTEOPOROSIS, CARDIOVASCULAR DISEASES, COGNITIVE DISORDERS, MENOPAUSAL SYMPTOMS, INCONTINENCE, OBESITY, DYSMENORRHEA, DYSFUNCTIONAL UTERINE BLEEDING, ACNE, HIRSUTISM, POST-PARTUM LACTATION | NOVO NORDISK A/S (DK) | 2001-11-13 | — | — | US | disclosed |
| US-20010021710-A1 | NOVEL CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-5994390-A | OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; UROGENITAL DISORDERS | NOVO NORDISK (DK) | 1999-11-30 | — | — | US | disclosed |
| US-5985306-A | (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes | NOVO NORDISK A/S (DK) | 1999-11-16 | — | — | US | disclosed |
| EP-0937059-A1 | NOVEL $i(TRANS)-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998018774-A1 | NOVEL TRANS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021710-A1 | NOVEL CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | CYP19A1, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885MLNR 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.